Understand disease progression, treatment behavior, and real-world outcomes

Longitudinal, person-level real-world data captured directly from individuals to support research, evidence generation, and decision-making across the product lifecycle.

Understand disease progression and behavior over time

• Analyze longitudinal patterns across symptoms, function, and daily context
• Observe health outside clinical encounters
• Understand disease progression beyond episodic claims data

Inform portfolio, pipeline, and evidence decisions

• Evaluate hypotheses using longitudinal, real-world data
• Identify and prioritize populations based on behavior and outcomes
• Strengthen investment decisions with contextual evidence

Enable advanced modeling and evidence development

• Define subgroups beyond demographics and claims
• Compare behavior and outcomes across populations over time
• Inform model development, protocol design, and commercial strategy

The Evidation Community: an ongoing connection to 5M people

*Varies by population, protocol, and length of program; many of our recent programs have seen 90%+ engagement

Scaled

• 1M+ Members have participated in research
• 97% of U.S. zip codes represented

Characterized

• 1.3B+ data points collected daily
• 100+ conditions represented

Engaged

• 90% average program engagement*
• 89% average response to content seen in app**

What you can understand with this data

Analyze disease progression, treatment behavior, and real-world outcomes using longitudinal, multimodal data collected over time.

Longitudinal, person-level data across behavior and outcomes: Access rich, historical data unified at the individual level, capturing how health, treatment, and behavior evolve over time across multiple dimensions. Data includes:

• Patient-reported outcomes and survey data
• Behavioral and functional measures
• Connected device and wearable data
• Clinical data
• Molecular data, where available

Deep population characterization for targeted analysis: Access condition-specific cohorts enriched with demographic, behavioral, and health attributes to identify subgroups, segment populations, and understand variation in outcomes.

Structured for analytics, modeling, and evidence generation: Receive datasets formatted for advanced analytics, model development, and secondary data linkage, enabling analysis of progression, behavior, and outcomes over time.

Flexible access to longitudinal data: License de-identified, individual-level datasets as a one-time extract or through a subscription model with recurring updates and continuous data enrichment.

See how we drive success for our customers:

Identifying and addressing gaps in the patient experience

Myovant uncovered significant unmet needs among individuals with uterine fibroids (UF) in a direct-to-patient 4-month study with 350 women living with UF.

• 92% weekly survey completion
• 85% daily survey completion

READ!

FluSmart participants receive alerts and nudges to seek care

In partnership with BARDA, Evidation developed and deployed a flu monitoring program, FluSmart, within the Evidation Community to collect rich, longitudinal data and activate high-risk participants into research and care.

• 200K+ individuals participated in FluSmart
• 90%+ engagement rate

READ!

Members who suffer from migraines receive personal health feedback

Evidation developed, and deployed, MigraineSmart, a symptom tracking health program that collects direct-from-participant data and provides educational content and personalized insights to participants, helping them better understand and manage their migraines.

• 3K+ individuals participated in the MigraineSmart program
• 48% said that tracking helps them better understand symptom patterns and migraine triggers

READ!

Therapeutic experience

• Autoimmune

• Cardiology

• Dermatology

• Mental Health

• Metabolic

• Neurology

• Respiratory

• Women's Health

• Vaccines and Infectious Diseases

Who we work with

Evidation partners include top biopharma companies, as well as consumer health companies, technology companies, non-profit organizations, and government agencies.